Alana T Brennan1, Kate Shearer, Mhairi Maskew, Lawrence Long, Ian Sanne, Matthew P Fox. 1. Center for Global Health & Development, Boston University, Boston, MA, USA; Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
OBJECTIVE: In April 2010, South Africa replaced stavudine with tenofovir in first-line antiretroviral therapy (ART) despite tenofovir's higher cost. We examined treatment outcomes over 24 months amongst patients initiated on tenofovir-based vs. stavudine-based first-line regimens. METHODS: Prospective cohort analysis of 3940 patients newly initiating either stavudine-based (April 2009 to March 2010) or tenofovir-based (April 2010 to March 2011) ART in Johannesburg, South Africa. Cox proportional hazards models and Fine and Gray's competing risk regression accounting for death were used to model mortality and loss to follow-up, respectively. Linear and log-binomial regression were used to evaluate associations with immunologic response and unsuppressed virus (≥ 400 copies/ml), respectively. RESULTS: About 1878 patients prescribed tenofovir and 2062 patients prescribed stavudine were included. One hundred and sixty-six (8.8%) tenofovir and 244 (11.8%) stavudine patients died. Three hundred and fifty (18.6%) tenofovir and 379 (18.4%) stavudine patients were lost to follow-up over 24 months on ART. Adjusted regression models showed tenofovir and stavudine were comparable regarding death, loss to follow-up, immunologic response and virologic status. CONCLUSIONS: We found no difference in mortality, loss to follow-up, immunological and virologic outcomes over the first 24-months on ART associated with tenofovir compared with stavudine.
OBJECTIVE: In April 2010, South Africa replaced stavudine with tenofovir in first-line antiretroviral therapy (ART) despite tenofovir's higher cost. We examined treatment outcomes over 24 months amongst patients initiated on tenofovir-based vs. stavudine-based first-line regimens. METHODS: Prospective cohort analysis of 3940 patients newly initiating either stavudine-based (April 2009 to March 2010) or tenofovir-based (April 2010 to March 2011) ART in Johannesburg, South Africa. Cox proportional hazards models and Fine and Gray's competing risk regression accounting for death were used to model mortality and loss to follow-up, respectively. Linear and log-binomial regression were used to evaluate associations with immunologic response and unsuppressed virus (≥ 400 copies/ml), respectively. RESULTS: About 1878 patients prescribed tenofovir and 2062 patients prescribed stavudine were included. One hundred and sixty-six (8.8%) tenofovir and 244 (11.8%) stavudinepatientsdied. Three hundred and fifty (18.6%) tenofovir and 379 (18.4%) stavudinepatients were lost to follow-up over 24 months on ART. Adjusted regression models showed tenofovir and stavudine were comparable regarding death, loss to follow-up, immunologic response and virologic status. CONCLUSIONS: We found no difference in mortality, loss to follow-up, immunological and virologic outcomes over the first 24-months on ART associated with tenofovir compared with stavudine.
Authors: Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2012-04-24 Impact factor: 4.177
Authors: Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne Journal: Int J Epidemiol Date: 2012-03-20 Impact factor: 7.196
Authors: Hamilton Domingos; Rivaldo Venâncio da Cunha; Anamaria Mello Miranda Paniago; Diego Mira Martins; Eduardo Brandão Elkhoury; Albert Schiaveto de Souza Journal: Braz J Infect Dis Date: 2009-04 Impact factor: 1.949
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Richard A Murphy; Henry Sunpath; Daniel R Kuritzkes; Francois Venter; Rajesh T Gandhi Journal: J Infect Dis Date: 2007-12-01 Impact factor: 5.226
Authors: Kamban Hirasen; Denise Evans; Mhairi Maskew; Ian M Sanne; Kate Shearer; Caroline Govathson; Given Malete; Sheryl A Kluberg; Matthew P Fox Journal: Clin Epidemiol Date: 2017-12-18 Impact factor: 4.790
Authors: Alana T Brennan; Jacob Bor; Mary-Ann Davies; Gilles Wandeler; Hans Prozesky; Geoffrey Fatti; Robin Wood; Kathryn Stinson; Frank Tanser; Till Bärnighausen; Andrew Boulle; Izukanji Sikazwe; Arianna Zanolini; Matthew P Fox Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 5.363
Authors: Samantha Kaplan; Katleho S Nteso; Nathan Ford; Andrew Boulle; Graeme Meintjes Journal: South Afr J HIV Med Date: 2019-12-18 Impact factor: 2.744